Clinical Trials Logo

Lymphoma, Large B-Cell, Diffuse clinical trials

View clinical trials related to Lymphoma, Large B-Cell, Diffuse.

Filter by:

NCT ID: NCT03450343 Completed - Clinical trials for Large B-Cell Diffuse Lymphoma

Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Start date: April 4, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of adding oral azacitidine to the chemotherapy combination R-ICE. This study will also look at whether or not disease outcomes improve with the combination.

NCT ID: NCT03424603 Completed - Multiple Myeloma Clinical Trials

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Start date: February 22, 2018
Phase: Phase 1
Study type: Interventional

First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 3 weeks.

NCT ID: NCT03399513 Completed - Clinical trials for Diffuse Large B Cell Lymphoma

Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma

R-CHOEP-brut
Start date: May 3, 2018
Phase: Phase 2
Study type: Interventional

This study will investigate if treatment results obtained with R-CHOEP in young high-risk patients with diffuse large B-cell lymphoma can be further improved by the addition of ibrutinib to this regimen.

NCT ID: NCT03378947 Completed - Clinical trials for To Characterize and Compare Clinical, Pathological and Molecular Features

EBV-associated Diffuse Large B Cell Lymphoma

Start date: June 1, 2017
Phase:
Study type: Observational

The aim of this study is to characterize and compare clinical, pathological (histology, immunophenotype) and molecular features of EBV-related GZL and DLBCL: do they belong to the same entity or to two different subtypes of EBV-related lymphoma ?

NCT ID: NCT03376958 Completed - Clinical trials for Diffuse Large B Cell Lymphoma

Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

Start date: January 1, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Apatinib for patients with Relapsed Refractory Diffuse Large B Cell Lymphoma.

NCT ID: NCT03372837 Completed - Clinical trials for Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL

Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

Start date: January 15, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy of SyB L-0501 in combination with rituximab in patients with recurrent/relapsed diffuse large B-cell lymphoma.

NCT ID: NCT03365791 Completed - Clinical trials for Small Cell Lung Cancer

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Start date: January 24, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.

NCT ID: NCT03364439 Completed - Clinical trials for Diffuse Large B Cell Lymphoma

R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients

FIL_DLCL10
Start date: January 2012
Phase: Phase 2
Study type: Interventional

Prospective, multicentre phase II study with R-CHOP- 14 or R-CHOP-21 & consolidation PET-oriented radiotherapy (RT) in diffuse large B cell lymphoma (DLBCL) patients

NCT ID: NCT03357627 Completed - Clinical trials for Lymphoma, Non-Hodgkin

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

Start date: February 16, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of TAK-659 and venetoclax when administered in combination in participants with non-Hodgkin lymphoma (NHL) relapsed and/or refractory after at least 1 prior line of therapy and to evaluate safety and tolerability of TAK-659 and venetoclax when administered in combination.

NCT ID: NCT03349450 Completed - Recurrent Clinical Trials

DPX-Survivac and Checkpoint Inhibitor in DLBCL

SPiReL
Start date: March 13, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase 2 non-randomized, open label, uncontrolled, efficacy and safety study. Study participants will receive two priming doses of 0.5mL of DPX-Survivac 21 days apart and up to six 0.1ml maintenance injections every two months with low dose metronomic oral cyclophosphamide (50 mg BID) for one year or until disease progression, whichever occurs first. Pembrolizumab 200 mg will be administered every 3 weeks for up to one year or until disease progression, whichever occurs first.